

DISCUSSIONS WITH LEADERS

667 Supporting Imaging at the Highest Level: Janet Eary Talks with Lale Kostakoglu About NCI Leadership in Advancing Imaging

Janet Eary and Lale Kostakoglu

STATE OF THE ART

670 Quantitative Brain Amyloid PET

William J. Jagust, Venkata S. Mattay, Daniel M. Krainak, Sue-Jane Wang, Lora D. Weidner, A. Alex Hofling, Hayoung Koo, Pamela Hsieh, Phillip H. Kuo, Gill Farrar, et al.

CONTINUING EDUCATION

679 Clinical Management of Advanced Prostate Cancer: Where Does Radiopharmaceutical Therapy Fit in the Treatment Algorithm?

Paul Viscuse, Michael Devitt, and Robert Dreicer

IS IT REALLY HAPPENING?

686 Is ^{161}Tb Really Happening?

Grace Kong, James P. Buteau, and Michael S. Hofman

ONCOLOGY

Clinical

688 [^{18}F]FET PET/MRI: An Accurate Technique for Detection of Small Functional Pituitary Tumors

Ilanah J. Pruis, Frederik A. Verburg, Rutger K. Balvers, Anita A. Harteveld, Richard A. Feelders, Meike W. Vernooij, Marion Smits, Sebastian J.C.M.M. Neggers, and Sophie E.M. Veldhuijzen van Zanten

693 Cancer Risk in Graves Disease with Radioactive ^{131}I Treatment: A Nationwide Cohort Study

Kyeong Jin Kim, Jimi Choi, Kyoung Jin Kim, Eyun Song, Ji Hee Yu, Nam Hoon Kim, Hye Jin Yoo, Ji A Seo, Nan Hee Kim, Kyung Mook Choi, et al.

700 Human Epidermal Growth Factor Receptor 2 (HER2) PET Imaging of HER2-Low Breast Cancer with [^{68}Ga]Ga-ABY-025: Results from a Pilot Study

Renske Altena, Siri af Burén, August Blomgren, Emelie Karlsson, Antonios Tzortzakakis, Nikolai Brun, Mohammad M. Moein, Emma Jussing, Fredrik Y. Frejd, Jonas Bergh, et al.

708 Optimal [^{18}F]FDG PET/CT Cutoff for Pathologic Complete Response in HER2-Positive Early Breast Cancer Patients Treated with Neoadjuvant Trastuzumab and Pertuzumab in the PHERGain Trial

Geraldine Gebhart, Marleen Keyaerts, Thomas Guiot, Patrick Flamen, Manuel Ruiz-Borrego, Agostina Stradella, Begoña Bermejo, Santiago Escrivá-de-Romani, Lourdes Calvo Martínez, Nuria Ribelles, et al.

714 High-Temporal-Resolution Kinetic Modeling of Lung Tumors with Dual-Blood Input Function Using Total-Body Dynamic PET

Yiran Wang, Yasser G. Abdelhafez, Benjamin A. Spencer, Rashmi Verma, Mamta Parikh, Nicholas Stollenwerk, Lorenzo Nardo, Terry Jones, Ramsey D. Badawi, Simon R. Cherry, et al.

722 ^{18}F -BMS-986229 PET to Assess Programmed-Death Ligand 1 Status in Gastroesophageal Cancer

Samuel L. Cytryn, Neeta Pandit-Taskar, Melissa A. Lumish, Steven B. Maron, Ping Gu, Geoffrey Y. Ku, Joanne F. Chou, Marinela Capanu, Ariel Antoine, Diane Loegel, et al.

Basic

728 ■ FEATURED BASIC SCIENCE ARTICLE. Noninvasively Deciphering the Immunosuppressive Tumor Microenvironment Using Galectin-1 PET to Inform Immunotherapy Responses

Ning Liu, Xiujie Yang, Chao Gao, Jianze Wang, Yuwen Zeng, Linyu Zhang, Qi Yin, Ting Zhang, Haoyi Zhou, Kui Li, et al.

THERANOSTICS

Clinical

735 ■ BRIEF COMMUNICATION. Real-World Experience with ^{177}Lu -PSMA-617 Radioligand Therapy After Food and Drug Administration Approval

Abuzar Moradi Tuchayi, Surekha Yadav, Fei Jiang, Sarasa T. Kim, Rachelle K. Saelee, Amanda Morley, Roxanna Juarez, Courtney Lawhn-Heath, Yingbing Wang, Ivan de Kouchkovsky, et al.

740 ■ FEATURED ARTICLE OF THE MONTH. First-in-Human Safety, Imaging, and Dosimetry of a Carbonic Anhydrase IX-Targeting Peptide, [^{68}Ga]Ga-DPI-4452, in Patients with Clear Cell Renal Cell Carcinoma

Michael S. Hofman, Ben Tran, Darren R. Feldman, Anna Pokorska-Bocci, Solen Pichereau, Jonathan Wessen, Mohammad B. Haskali, Richard B. Sparks, Olena Vlasjuk, and Ivana Galetic

744 Kick-Starting Molecular Theranostics in Renal Cell Carcinoma

Viktor Grünwald, Boris Hadschik, Niklas Klümper, and Ken Herrmann

746 Effectiveness and Safety of Retreatment with ^{177}Lu -DOTATATE in Patients with Progressive Neuroendocrine Tumors: A Retrospective Real-World Study in the United States

Ebrahim S. Delpassand, Soheil M. Yazdi, Shashank Ghantaji, Antonio Nakasato, Corinne Strickland, Rodolfo Nunez, Afshin Shafie, Susan Cork, Clare Byrne, Jackson Tang, et al.

753 SPECT/CT Image-Derived Absorbed Dose to Red Marrow Correlates with Hematologic Toxicity in Patients Treated with [¹⁷⁷Lu]Lu-DOTATATE

Johan Blakkisrud, Avery B. Peterson, Scott J. Wildermann, Griffen Kingkiner, Ka Kit Wong, Chang Wang, Kirk A. Frey, Caroline Stokke, and Yuni K. Dewaraja

Basic

761 Preclinical Characterization of DPI-4452: A ⁶⁸Ga/¹⁷⁷Lu Theranostic Ligand for Carbonic Anhydrase IX

Frédéric Massière, Norbert Wiedemann, Inés Borrego, Aileen Hoehne, Frank Osterkamp, Matthias Paschke, Dirk Zboralski, Anne Schumann, Anne Bredenbeck, Franck Brichory, et al.

CARDIOVASCULAR

Clinical

768 Artificial Intelligence Predicts Hospitalization for Acute Heart Failure Exacerbation in Patients Undergoing Myocardial Perfusion Imaging

Attila Feher, Bryan Bednarski, Robert J. Miller, Aakash Shanbhag, Mark Lemley, Leonidas Miras, Albert J. Sinusas, Edward J. Miller, and Piotr J. Slomka

Basic

775 Development of a CD163-Targeted PET Radiotracer That Images Resident Macrophages in Atherosclerosis

Xiuli Zhang, Gyu Seong Heo, Alexandria Li, Divangana Lahad, Lisa Detering, Joan Tao, Xuefeng Gao, Xiaohui Zhang, Hannah Luehmann, Deborah Sultan, et al.

NEUROLOGY

Clinical

781 Impact of PET Reconstruction on Amyloid- β Quantitation in Cross-Sectional and Longitudinal Analyses

Gihan P. Ruwanpathirana, Robert C. Williams, Colin L. Masters, Christopher C. Rowe, Leigh A. Johnston, and Catherine E. Davey

Basic

788 Robust Quantification of Phosphodiesterase-4D in Monkey Brain with PET and ¹¹C-Labeled Radioligands That Avoid Radiometabolite Contamination

Meijuan Jiang, Shiyu Tang, Madeline D. Jenkins, Adrian C. Lee, Bruny Kenou, Carson Knoer, Jose Montero Santamaria, Shawn Wu, Jieih-San Liow, Sami S. Zoghbi, et al.

RADIOBIOLOGY/DOSIMETRY

Basic

794 MIRD Pamphlet No. 29: MIRDy90—A ⁹⁰Y Research Microsphere Dosimetry Tool

Harry Marquis, Juan C. Ocampo Ramos, Lukas M. Carter, Pat Zanzonico, Wesley E. Bolch, Richard Laforest, and Adam L. Kesner

AI/ADVANCED IMAGE ANALYSIS

Basic

803 Impact of ¹⁸F-FDG PET Intensity Normalization on Radiomic Features of Oropharyngeal Squamous Cell Carcinomas and Machine Learning-Generated Biomarkers

Stefan P. Haider, Tal Zeevi, Kariem Sharaf, Moritz Gross, Amit Mahajan, Benjamin H. Kann, Benjamin L. Judson, Manju L. Prasad, Barbara Burtness, Mariam Aboian, et al.

810 ISIT-QA: In Silico Imaging Trial to Evaluate a Low-Count Quantitative SPECT Method Across Multiple Scanner-Collimator Configurations for ²²³Ra-Based Radiopharmaceutical Therapies

Zekun Li, Nadia Benabdallah, Jingqin Luo, Richard L. Wahl, Daniel L.J. Thorek, and Abhinav K. Jha

THE ILLUSTRATED POST

818 PSMA PET/CT Dual-Time-Point Imaging: Nice to Have or Need to Have?

Lena M. Unterrainer, Kathleen Ruchalski, Martin S. Allen-Auerbach, Jeremie Calais, and Matthias R. Benz

THE ILLUSTRATED POST

820 [⁶⁸Ga]Ga-FAPI-46 PET in a Borderline Ovarian Tumor

Lena M. Unterrainer, Sanaz Memarzadeh, Neda A. Moatamed, Matthias R. Benz, Johannes Czernin, and Jeremie Calais

LETTERS TO THE EDITOR

822 ⁶⁴Cu-DOTA Enables Late PET Imaging and Leak Detection in the Cerebrospinal Fluid Space

Robert Drescher, Julia Greiser, Sebastian Gröber, Thomas Weisheit, and Martin Freesmeyer

IN MEMORIAM

823 Gerald L. DeNardo, MD, 1932–2024

DEPARTMENTS

10A This Month in JNM

809 Errata